5 ms·
The cost of developing drugs is high because of all the drugs that fail, after requiring lots of money to develop. You can't just look at the successful drug an
by kazinator 3y ago
The cost of developing drugs is high because of all the drugs that fail, after requiring lots of money to develop. You can't just look at the successful drug and say that's the cost. There are drugs that don't get to the trial stage, so also you can't just look at trials, even if you include failed ones.
The researchers cited in this article seem to be promulgating the fallacy that we need only look at the cost of a successful drug trial, and that's the cost. The drugs magically appeared out of nowhere, for free, and equally magically, they are working drugs, so we already know our trial will succeed. It's just a charade we have to go pay for to get the government's rubber stamp, and then it's all good!
- redserk 3y agoWhat about the public funding that led to research and presumably went towards some of the failed attempts? It sounds like there’s simply not enough information to gauge if pharmaceutical companies are being honest about their claims of R&D costs.
- lotsofpulp 3y agoThere is nothing stopping governments around the world from spending money to do their own R&D and conduct their clinical trials.
- rysertio 3y agoThey do. But then the patents gets leeched by big pharma companies investing a fraction of the development costs.
- lotsofpulp 3y agoWhy does the government allow big pharma companies to “leech” the patent? What does that even mean? Can you describe the steps by which big pharma obtains the patent?
- kazinator 3y agoIf the government hands out grants, about which information is subsequently hard to get, that points to a gaping transparency issue squarely on the government side. Pharma R&D companies that are publicly listed should have some information about their balance sheets. Private equity ones are going to be the most opaque. That's kind of their prerogative.
- ramraj07 3y agoI used to be in the academic side of the so-called industry and I can tell you that most drugs fail because of horrendously bad decisions and hypotheses. Most companies make decisions on what drugs to take to trial on stupidly misleading preclinical data and have been graciously rewarded for their mistakes with no consequences.
- refurb 3y agoThere is no "academic side" of the pharmaceutical industry. There is just academia. And the goal of academia (publishing) are very different than the industry (identifying a new drug).
- hcknwscommenter 3y agoAgree. I don't think there is any signal from the "academic side" of this discussion. All of the detailed relevant information is very proprietary. I know multiple large players in the industry that share huge amounts of data with academics regularly, but not that data. Decision makers are informed by internal experts with just as many bona fides (and more) than academic peers. Having been in both worlds, and admittedly in my opinion only, academics do well to move their technical fields forward into new and exciting and useful science medicine and economics but do little (well nothing really) in delving into or even accessing the actual data that directly informs clinical trial decisions. That said, I can totally understand why Pharma clinical trial decisions are baffling to academics. E.g., why did aduhelm go forward to (conditional) market approval? That one is baffling to me, but I don't have the data:) [edit] I'm going to add something here. The grandparent refers to "stupidly misleading pre-clinical data." Pre-clinical data informs very inexpensive (relatively) Phase I studies. And there is a ton of it. You might have potentially misleading pre-clinical data that suggests the possibility of an entirely new therapeutic mechanism of action for a huge unmet need coupled with massive amounts of pre-clinical data that demonstrates a near certainty that the intervention will be safe. That's the entire point of moving forward to a Phase I or Ib (or maybe even II) study. The 1000x-10,000x more expensive phase 3's are not relying on pre-clinical studies.
- 3y ago
- LorenPechtel 3y agoYup. Only a small fraction of drugs ever make it to human testing. The winners have to pay for all the losers and then some (consider: You can play a game where you bet $1 and have a 1 in 10 chance of getting $10. Completely fair, but if you play long enough you're guaranteed to go bankrupt.) There's also the time factor. Suppose you spend $100M to develop and sell a drug that brings in a total of $150M over it's on-patent lifetime. You *lost* money.